1 TG Dekker – WHO, MalaysiaFeb 2005
Active Pharmaceutical Ingredients (APIs)
Workshop on GMP and Quality Assurance of
Multisource Tuberculosis MedicinesKuala Lumpur – Malaysia
21-25 February 2005
Theo Dekker, D.Sc., consultant to WHOResearch Institute for Industrial Pharmacy
North-West University, Potchefstroom, South [email protected]
2 TG Dekker – WHO, MalaysiaFeb 2005
Abbreviations
API Active pharmaceutical ingredientBP British PharmacopoeiaCEP EU certificate of suitabilityEOI Expression of interestFDC Fixed dose combinationFPP Finished pharmaceutical productGMP Good manufacturing practicesICH International Conference on HarmonizationInt.Ph. International PharmacopoeiaPh.Eur. European PharmacopoeiaSmPC Summary of product characteristicsTB TuberculosisUSP United States Pharmacopeia
3 TG Dekker – WHO, MalaysiaFeb 2005
Presentation approach
1. Collect and interpret all available information on the APIs (pre-dossier studies): The possible manufacturer(s) Literature, all aspects Monographs in pharmacopoeia
2. Dossier requirements Nomenclature Properties Manufacturing and site Specifications Container closure Stability testing / re-test period
4 TG Dekker – WHO, MalaysiaFeb 2005
Part 1. Available information on API
Collecting and interpretation of all available information of the API through a systematic approach, should always be done upfront. Some outcomes:1. Sound choice of API source (manufacturer)2. Sound scientific understanding of the API, with
respect to properties, stability, specifications, etc.3. Assists in FPP pharmaceutical development4. Assists in dossier compilation5. Reduction of time / cost
Forms part of Product Profile Report
5 TG Dekker – WHO, MalaysiaFeb 2005
Info on potential API manufacturer(s)
The decision on the API manufacturer should be finalised before starting or early during
FPP development studies
Changes afterwards may be major of nature
1. Is the manufacturer reliable / reputable?
2. Is the open part of DMF available and according to all requirements?
3. Is a valid CEP available?
4. GMP inspection of API site by FPP manufacturer
6 TG Dekker – WHO, MalaysiaFeb 2005
DMFs accepted & CEPs by Jan 2005
Number of manufacturers
API DMF CEP
Ethambutol 2HCl 2 1
Isoniazid 3 1
Pyrazinamide 3 3
Rifampicin 5
Streptomycin 1
Total 14 5
7 TG Dekker – WHO, MalaysiaFeb 2005
Literature information
Know your API before development, through: Standard works / series / books – such as:
(Analytical) Profiles of Drug Substances and Excipients [ed: (Florey) Brittain) – 30 volumes]
The Merck Index (for structures, properties) Pharmaceutical Codex (12th edition)
Journals through search facilities such as International Pharmaceutical Abstracts, Chemical
Abstracts, Analytical Abstracts & internet Pharmacopoeial monographs (current) Analysis of structure & stereochemistry
8 TG Dekker – WHO, MalaysiaFeb 2005
9 TG Dekker – WHO, MalaysiaFeb 2005
Examples of existing API information in standard works
In the table on the next pages it is indicated in which standard works the APIs, appearing in the 5th invitation for Expression of Interest (TB), is included. Abbreviations: Apr = Analytical Profiles of Drug Substances and Excipients (contains chapters on APIs) BP = British Pharmacopoeia Cod = Pharmaceutical Codex (12th ed, 1994) EP = Ph.Eur. Int = International Pharmacopoeia US = USP MI = Merck Index (13th ed, 2001)
10 TG Dekker – WHO, MalaysiaFeb 2005
Table of API occurrence
API APr Cod BP EP US Int MI
Rifampicin (rifampin) ✓ ✓ ✓ ✓ ✓ ✓ ✓
Ethambutol 2HCl ✓ ✓ ✓ ✓ ✓ ✓ ✓
Pyrazinamide ✓ ✓ ✓ ✓ ✓ ✓
Isoniazid ✓ ✓ ✓ ✓ ✓ ✓ ✓
Streptomycin sulfate ✓ ✓ ✓ ✓ ✓ ✓
Amikacin ✓ ✓ ✓ ✓ ✓ ✓ ✓
Kanamycin ✓ ✓ ✓ ✓ ✓
Capreomycin ✓ ✓ ✓
11 TG Dekker – WHO, MalaysiaFeb 2005
Table of API occurrence (con.)
Apology: JP was not available at time of preparation
API APr Cod BP EP US Int MI
Cycloserine ✓ ✓ ✓
Ethionamide ✓ ✓ ✓ ✓ ✓
Ofloxacin ✓ ✓ ✓ ✓
Protionamide ✓ ✓
p-Aminosalicylic acid ✓ ✓ ✓
Moxifloxacin ✓
12 TG Dekker – WHO, MalaysiaFeb 2005
Example: solubility from2 literature sources
1 Merck Index 13th ed 2 Pharmaceutical Codex 12th ed
API Water CHCl3 Ethanol
Rifampicin Water: Slightly 1,2
pH 7.5: 0.3% 2
pH 5.3: 0.4% 2
pH 2.0: 10% 2
Freely 1,2 Slightly 2
Ethambutol 2HCl 50% 2 0.1% 2 20% 2
Ethambutol base Sparingly 2 Very 2
Isoniazid 14% 1 0.1% 1 2% 1
Pyrazinamide 1.5% 1 0.7% 1 0.6% 2
13 TG Dekker – WHO, MalaysiaFeb 2005
Information from the structures
APIs which are organic compounds, have unique chemical structures & stereochemistry
These structures, together with the solid/liquid state conditions, are basically responsible for chemical and physical properties of the APIs
It is thus always appropriate to analyse the structure of the API, especially if limited literature information is available
Few examples to follow
14 TG Dekker – WHO, MalaysiaFeb 2005
Rifampicin structure
hydrolysis
oxidation hydrolysis
15 TG Dekker – WHO, MalaysiaFeb 2005
3-Formyl rifamycin formation
Source: S. Singh et al. Pharm. Pharmacol. Commun., 6, 405-410 (2000)
16 TG Dekker – WHO, MalaysiaFeb 2005
Rifampicin structure and properties
Oxidation Hydroquinone group
Main degradation of API (to rifampicin quinone) Enhances solubility in alkaline medium
Tertiary amine Moderately prone towards oxidation (to N-oxide) Enhances solubility in acid medium
Oxidation enhanced by Metal ions Low pH
17 TG Dekker – WHO, MalaysiaFeb 2005
Rifampicin structure and properties (2)
Hydrolysis Hydrazone (imine) group
Hydrolysis to 3-formyl rifamycin 25-acetyl (ester) group
Hydrolysis to 25-desacetyl rifampicin (minor)
Light sensitive Due to conjugation in molecule (unsaturated)
Storage of bulk raw material (BP/Ph.Eur.): Store under nitrogen in an airtight container,
protected from light at temperature of ≤ 25ºC
18 TG Dekker – WHO, MalaysiaFeb 2005
Rifampicin impurities (TLC)
Reference: Int.Ph. related substances test for rifampicin
• Silica gel R1
• CHCl3/methanol : 85/15
• Daylight detection BP limits for capsules:-
a) Rifampicin: 20 mg/ml
b) Quinone: 0.8 mg/ml (4.0%)
c) N-oxide: 0.3 mg/ml (1.5%)
d) 3-Formylrifamycin: 0.1 mg/ml (0.5%)
e) Rifampicin: 0.2 mg/ml (1.0%)
19 TG Dekker – WHO, MalaysiaFeb 2005
Isoniazid structure
Small molecule (quite stable) Basic amino functions Primary amine - react with aldehydes/lactose (see
presentation: Pharmaceutical R&D Considerations) Can hydrolyze under stress conditions to inter alia
isonicotinic acid & hydrazine Oxidize in presence of strong oxidants (e.g.
permanganate), with metals as catalyst
20 TG Dekker – WHO, MalaysiaFeb 2005
Pyrazinamide structure
Small molecule (quite stable) Basic amino functions (in aromatic ring) Amide group can hydrolyse under strong conditions to
pyrazinoic acid & ammonia USP ID test C: Boil 20 mg with 5 ml of 5 N sodium
hydroxide: the odor of ammonia is perceptible Forms metal complexes (slight pink bulk API / product?) Sublimes when heated
21 TG Dekker – WHO, MalaysiaFeb 2005
Pyrazinamide synthesis
Reagents: NaOH, water as solvent, touch of EDTA Product directly crystallised from the reaction mixture No residual solvents (only water used) 2-CPZ to be included as a possible synthesis impurity in
API specifications EDTA for metal complexation (prevent colouration)
22 TG Dekker – WHO, MalaysiaFeb 2005
Ethambutol hydrochloride structure
Small molecule Basic amino groups (in free base) No vulnerable groups for degradation under mild
conditions (2-aminobutanol – synthesis impurity) 2 chiral carbon atoms, optically active (test) Hygroscopic (solubility in water: 50% m/m) Can dissolve in absorbed water at high relative humidity Forms metal complexes USP: Preserve in well-closed containers
23 TG Dekker – WHO, MalaysiaFeb 2005
p-Aminosalicylic acid
+ CO2
Carboxylic acid and phenolic group: acidic Weak basic group (amphoteric) Saturated solution: pH of 3.0-3.5 (USP) Sodium salt available (monograph in USP) Labile: Decarboxylate when heated Limit test for m-aminophenol in USP (API & tablets) More stable in alkaline medium than in acid medium Store in cool place!!
24 TG Dekker – WHO, MalaysiaFeb 2005
Cycloserine
R-configuration
Optically active H20
Stable in anhydrous solid state, protected from water Degrades in solution, or when solid is exposed to moisture Pathway1: Dimerisation through one molecule attacking other Pathway 2: Hydrolysis to ß-aminoxy-D-alanine Stability: alkaline medium > neutral >> acid medium Dissolution medium capsules: buffer pH 6.8 !!! (USP) Primary amine: react with aldehydes/ketones
25 TG Dekker – WHO, MalaysiaFeb 2005
Ofloxacin Moxifloxacin
Structurally related as encircled (see also ciprofloxacin) Both APIs contain acid and basic groups Chirality: both intrinsic chiral (optically active)
Ofloxacin: 1 chiral centre: racemate (±) used Moxifloxacin: 2 chiral centra: S,S-enatiomer used
Both APIs have enone system (in circle): photosensitive?
26 TG Dekker – WHO, MalaysiaFeb 2005
Amikacin – semi synthetic
Kanamycin
APIs differ only here
4 x NH2 groups, 2H2SO4 salt hydrolysis
27 TG Dekker – WHO, MalaysiaFeb 2005
Literature information sources
The information on the APIs mentioned in the previous slides are backed by inter alia: Analytical Profiles of Drug Substances and
Excipients (ed: Florey/ Brittain) (see next slide) The Pharmaceutical Codex: Principles and
Practice of Pharmaceutics. 1994. Lund, W., ed. 12th edition, London: The Pharmaceutical Press
The Merck Index, 13th edition (2001)
28 TG Dekker – WHO, MalaysiaFeb 2005
Literature support style
Literature information used in the dossier should always be accompanied by
Full traceable reference citations, for instance: Devani, M.B., Shishoo, C.J., Doshi, K.J. & Patel,
H.B. Kinetic studies of the interaction between isoniazid and reducing sugars. Journal of Pharmaceutical Sciences, 74, 427-432 (1985)
Hassan, M.M.A., Jado, A.I., & Zubair, M.U. Aminosalicylic acid. In Florey, K., ed. Analytical Profiles of Drug Substances, vol. 10. New York: Academic Press, p. 1-27 (1981)
Photocopies of the relevant pages
29 TG Dekker – WHO, MalaysiaFeb 2005
Part 2. Dossier requirements for Active pharmaceutical ingredient (API)
Refer to Section 2 of:
Guideline on Submission of Documentationfor Prequalification of Multi-source (Generic) Finished Pharmaceutical Products (FPPs)
used in the Treatment of HIV/AIDS, Malaria and Tuberculosis (hand-out)
As from page 3/33
30 TG Dekker – WHO, MalaysiaFeb 2005
Part 2. Dossier requirements for Active pharmaceutical ingredient (API) 3/33
2.1 Nomenclature (INN, Systematic, CAS, etc.)2.2 Properties (structure, stereochemistry, etc)2.3 Site of manufacture2.4 Route of synthesis (impurities, etc)2.5 Specifications (pharmacopoeia?)2.6 Container closure system2.7 Stability testing – re-test period & storage-
Open part of Drug Master File - submit (DMF) CEP (only limited information required)
31 TG Dekker – WHO, MalaysiaFeb 2005
2.2 Properties of APIs 3/33
Three aspects:
2.2.1 API not described in BP, Int.Ph., JP, Ph.Eur., or USP (non-compendial)
2.2.2 API described in BP, Int.Ph., JP, Ph.Eur., or USP (compendial)
2.2.3 Information from literature (discussed)
All the APIs on 5th Invitation for EOI fall in category 2.2.2, except moxifloxacin
32 TG Dekker – WHO, MalaysiaFeb 2005
2.2.1 Properties non-compendial APIs
Structure, stereochemistry, MF and RMM Proof of structure/stereochemistry correctness
Single crystal X-ray structure (sufficient) or Spectrometric data (IR, 1H & 13C NMR, MS, etc.) in form of
QA certified copies of the spectra and tabulated of data with- assignments against structure or- correlation against API spectral data from peer reviewed literature, preferable by the innovator (in tabulated form!!). Strongly recommended for non-compendial APIs
Physico-chemical properties as discussed on next slide
33 TG Dekker – WHO, MalaysiaFeb 2005
2.2.2 Properties compendial APIs
Physicochemical and other relevant properties of the API, such as Solubility in water, other solvents such as ether, ethanol,
acetone, and buffers of different pH pKa, partition coefficient Existence/absence of polymorphs and pseudo-polymorphs
e.g. solvates (with XRPD, DSC, IR) Polymorphism: see presentation Pharmaceutical R&D
Considerations (rifampicin) Hygroscopicity: see presentation Pharmaceutical R&D
Considerations (ethambutol hydrochloride in 4FDC tablet) Particle size
34 TG Dekker – WHO, MalaysiaFeb 2005
2.3 Sites of manufacture 3/33
For each facility where all/part of manufacturing occurs: Name of manufacturer Street address Postal address Phone & fax numbers E-mail addresses
35 TG Dekker – WHO, MalaysiaFeb 2005
2.4 Route(s) of synthesis 4/33
Three aspects:
2.4.1 API not described in BP, Int.Ph., JP, Ph.Eur., or USP (non-compendial)
2.4.2 API described in BP, Int.Ph., JP, Ph.Eur., or USP (compendial)
2.4.3 Specifications of raw materials and intermediates used in the synthesis
36 TG Dekker – WHO, MalaysiaFeb 2005
2.4.1 Synthesis non-compendial APIs
A flow diagram of the synthesis process, that includes inter alia chemical structures of starting materials and intermediates, reagents, catalysts, conditions, solvents and purification steps Example: see pyrazinamide synthesis (slide 21)
A full description of each process, including purification and reprocessing (justified)
(Possible) process impurities should be discussed: Organic compounds Catalysts and other inorganic impurities Residual solvents
37 TG Dekker – WHO, MalaysiaFeb 2005
2.4.2 Synthesis compendial APIs
Valid CEP available Only outline of synthesis necessary
No CEP Same as for non-compendial APIs
38 TG Dekker – WHO, MalaysiaFeb 2005
2.5 API specifications 4/33
2.5.1 API not described in BP, Int.Ph., JP, Ph.Eur., or USP (non-compendial)
2.5.2 API described in BP, Int.Ph., JP, Ph.Eur., or USP (compendial)
General note
An API has only one set of specifications, applicable at release and throughout the re-test period (FPPs may have two sets of specifications)
39 TG Dekker – WHO, MalaysiaFeb 2005
2.5.1 Specs: non-compendial APIs
ICH Q6A (new APIs and products) – for instance: Provide justification for proposed specifications Impurities (synthesis, degradation & residual
solvents) to be characterised and limits set Analytical methods with validation Preparation and potency determination/specification
of primary and secondary (working) standards, with CoAs
Valid CoAs for at least 2 batches
40 TG Dekker – WHO, MalaysiaFeb 2005
2.5.2 Specs: compendial APIs
Additional critical specifications not included in monograph e.g. particle size & polymorphic form synthesis related impurities residual solvents
Valid CoAs for at least 2 batches
2.5.3 Container-closure system for API 4/33
see guideline
41 TG Dekker – WHO, MalaysiaFeb 2005
2.7 Stability testing 6/33
2.7.1 Stress testing (forced degradation)
2.7.2 Stability testing (regulatory)
42 TG Dekker – WHO, MalaysiaFeb 2005
2.7.1 Forced degradation
Literature information and/or CEP in support or to replace studies
Forced degradation studies To identify possible degradants for stability
studies To verify specificity of stability assay method
- Diode array detection for API peak purity!! Different stress conditions in solution (guideline) Different stress conditions in solid state
(guideline)
43 TG Dekker – WHO, MalaysiaFeb 2005
2.7.2 Stability testing (regulatory)
Only degradants that form under the real-time and accelerated conditions needs to be considered
Stability protocol, particulars of batches (3), tabulated results and discussion of data
Typical schedule given under FPPs Propose re-test period when stored under
defined conditions
44 TG Dekker – WHO, MalaysiaFeb 2005
Some conclusions
1. Get to know your API by Analysis of literature information Analysis of the structures / functional groups Lab studies, e.g. forced degradation, spectral
data and physical data Considering the dossier requirements
2. Decision on API manufacturer should include DMF quality, GMP inspection, CEP availability
3. API manufacturers are encouraged to apply for CEPs for their APIs
Top Related